UNIVEC Selected By Johns Hopkins
Posted on: Monday, 21 November 2005, 12:00 CST
Univec, Inc. (OTCBB: UNVC) a specialty pharmaceutical, auto-disabled and safety syringe healthcare organization announced that it completed an agreement with Johns Hopkins Hospital to provide a specialty pharmaceutical for its medical facilities.
Raphael Langford, Executive Vice President and COO of Univec stated. "This is a time of excitement for the company to be selected by Johns Hopkins. We look forward to building on this relationship."
About Univec
Founded in 1992, Univec is a specialty pharmaceutical, auto-disable safety syringes healthcare organization. The Company license, manufactures, distributes and markets specialty pharmaceuticals and healthcare products.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a division of Univec assists pharmaceutical companies in the promotion and payment of prescription drugs though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples directly to physicians reducing potential liability and including the pharmacist in the clinical oversight and drug interaction checks for the patient.
Forward Looking Statements
This document contains forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec's business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec's reports to the Securities and Exchange Commission, which include Univec's Annual Report on Form 10-K. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec's reports filed with the Securities and Exchange Commission.
Source: Business Wire
Related Articles
- Catholics for Choice Statement on Healthcare Reform Bill
- PhRMA Statement on Healthcare Reform Coalition
- Molecular Insight Pharmaceuticals, Inc. Adds Four Healthcare Industry Experts to Board of Directors
- Absolute Software Identifies Top Five Computer Security Risks for Healthcare
- Newly Formed Council Issues Statement on Healthcare Provider Gaps Related to Education and Management of Fibromyalgia Syndrome
- Auriga Laboratories Announces the Formation of A.T.S. Pharmaceuticals, a Specialty Division Dedicated to Dermatology and Gastroenterology
- An Example of a Value-Added Chain Extending From Commodities Through Fine Chemicals to a Pharmaceutical Specialty Is Shown Inside the Book Titled Fine Chemicals: The Industry and the Business
- Anthera Pharmaceuticals Secures $36M Venture Financing to Initiate Clinical Programs
- Review of Cubist Pharmaceuticals sNDA for CUBICIN Moves Forward at FDA
- The Haelan Group and Healthwise Join Forces to Inform and Empower At-Risk Healthcare Consumers
 |
 |
User Comments (0)
RSS Feeds